Back to top
more

STERIS (STE)

(Delayed Data from NYSE)

$228.43 USD

228.43
590,247

+1.56 (0.69%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $228.48 +0.05 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Factors Likely to Shape Tenet Healthcare's (THC) Q2 Earnings

by Zacks Equity Research

Tenet Healthcare's (THC) second-quarter results are likely to reflect the impact of lower contribution of the Hospital segment to overall revenues. The results might partly benefit from a downtrend in operating expenses.

Zacks Equity Research

Is a Beat Likely for Intuitive Surgical (ISRG) in Q2 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.

Zacks Equity Research

AngioDynamics (ANGO) Q4 Earnings in Line, Revenues Beat Mark

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in Med Tech and Med Device businesses, as well as in its GBUs, in fourth-quarter fiscal 2022.

Zacks Equity Research

How Much Upside is Left in Steris (STE)? Wall Street Analysts Think 29%

by Zacks Equity Research

The mean of analysts' price targets for Steris (STE) points to a 29.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

3 Reasons Why Steris (STE) Is a Great Growth Stock

by Zacks Equity Research

Steris (STE) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) owing to its robust segmental results and the ongoing Cantel Medical integration.

Zacks Equity Research

Steris (STE) Up 1.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Hold STERIS (STE) Stock in Your Portfolio

by Zacks Equity Research

Investors are optimistic about STERIS (STE) due to its strong fiscal fourth-quarter results.

Zacks Equity Research

STERIS (STE) Q4 Earnings Surpass Estimates, Gross Margin Rises

by Zacks Equity Research

Robust performances across all four reporting segments drive STERIS' (STE) fiscal fourth-quarter revenues.

Zacks Equity Research

STERIS (STE) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Healthcare and AST arms is expected to have driven STERIS' (STE) fourth-quarter revenues.

Zacks Equity Research

Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in base business and raised 2022 outlook.

Zacks Equity Research

Globus Medical (GMED) Stock Fell on Preliminary Q1 Sales Results

by Zacks Equity Research

Globus Medical's (GMED) Q1 preliminary sales results reflect an increase in procedural volumes along with growth in Enabling Technologies business.

Zacks Equity Research

Zacks Industry Outlook Highlights Alcon, STERIS and Abiomed

by Zacks Equity Research

Alcon, STERIS and Abiomed have been highlighted in this Industry Outlook article.

Zacks Equity Research

Here's Why You Should Retain Bio-Rad (BIO) Stock For Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) owing to a recovery in most of its key global markets as well as an uptick in demand for COVID-related products.

Zacks Equity Research

Thermo Fisher (TMO) Debuts GMP-Manufactured Cas9 Protein

by Zacks Equity Research

Thermo Fisher's (TMO) Gibco CTS TrueCut Cas9 Protein to support genome editing for research and manufacturing applications.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Despite Industry Headwinds

by Urmimala Biswas

The Zacks Medical - Instruments industry is growing on R&D investments. ALC, STE and ABMD are set to gain the most. Yet, demand for non-COVID businesses is on the decline with the new COVID variant disrupting the trend.

Zacks Equity Research

Henry Schein (HSIC) Stock Moves Up 20.6%: What's Driving It?

by Zacks Equity Research

Henry Schein's (HSIC) stock rallied on strong fourth-quarter performance and bullish 2022 EPS guidance.

Zacks Equity Research

Here's Why You Should Hold on to Insulet (PODD) Stock For Now

by Zacks Equity Research

Investors are optimistic about Insulet (PODD) on robust uptake of the Omnipod system and bullish guidance.

Zacks Equity Research

STERIS (STE) Up 8% Since Q3 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) robust segmental growth and noteworthy acquisitions in the healthcare and pharmaceutical spaces.

Zacks Equity Research

STERIS (STE) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on impressive growth across its operating segments.

Zacks Equity Research

Here's Why You Should Retain STERIS (STE) Stock For Now

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) robust segmental performance and upbeat 2022 guidance.

Zacks Equity Research

Why Is Steris (STE) Down 3.7% Since Last Earnings Report?

by Zacks Equity Research

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

STERIS (STE) Strategic Buyouts Aid Growth, Margin Woe Stays

by Zacks Equity Research

STERIS' (STE) significant revenues from acquisitions of Key Surgical and Cantel Medical appear promising.

Zacks Equity Research

Here's Why You Should Hold on to STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on its better-than-expected earnings in the fiscal third quarter and the ongoing integration of the Cantel Medical business.

Zacks Equity Research

STERIS (STE) Q3 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

STERIS (STE) reports better-than-expected earnings for the third quarter of fiscal 2022 and robust segmental growth driving the top line.